Is AMD Stock an All-Time Buy?
Advanced Micro Devices (NASDAQ:AMD) is a high-growth AI stock that…
Sell
38
WVE Quote, Financials, Valuation and Earnings
Last price:
$13.07
Seasonality move
:
-4.34%
Day range:
$13.03 - $13.54
52-week range:
$3.50 - $16.74
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
31.57x
P/B ratio:
14.52x
Volume:
420.4K
Avg. volume:
1.1M
1-year change:
169.06%
Market cap:
$2.1B
Revenue:
$113.3M
EPS (TTM):
-$1.11
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
WVE
WAVE Life Sciences
|
$13.1M | -$0.30 | -11.91% | -61.85% | $22.30 |
|
EUDA
EUDA Health Holdings
|
$2.3M | -$0.02 | 1702.91% | -92.93% | -- |
|
GDTC
CytoMed Therapeutics
|
$130K | -$0.04 | -- | -- | -- |
|
HAWPF
Haw Par
|
-- | -- | -- | -- | -- |
|
MNDR
Mobile-health Network Solutions
|
-- | -- | -- | -- | -- |
|
RAFLF
Raffles Medical Group
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
WVE
WAVE Life Sciences
|
$13.48 | $22.30 | $2.1B | -- | $0.00 | 0% | 31.57x |
|
EUDA
EUDA Health Holdings
|
$4.50 | -- | $167.2M | -- | $0.00 | 0% | 64.70x |
|
GDTC
CytoMed Therapeutics
|
$2.80 | -- | $32.3M | -- | $0.00 | 0% | -- |
|
HAWPF
Haw Par
|
$8.35 | -- | $1.8B | 10.66x | $0.15 | 3.6% | 10.45x |
|
MNDR
Mobile-health Network Solutions
|
$0.31 | -- | $10.8M | -- | $0.00 | 0% | 0.77x |
|
RAFLF
Raffles Medical Group
|
$0.67 | -- | $1.2B | 27.83x | $0.02 | 2.66% | 2.41x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
WVE
WAVE Life Sciences
|
-- | -0.257 | -- | 1.82x |
|
EUDA
EUDA Health Holdings
|
-69.68% | 1.387 | 2.25% | 0.07x |
|
GDTC
CytoMed Therapeutics
|
-- | -2.052 | -- | -- |
|
HAWPF
Haw Par
|
0.97% | -0.006 | 1.68% | 27.90x |
|
MNDR
Mobile-health Network Solutions
|
-- | 0.000 | -- | 2.20x |
|
RAFLF
Raffles Medical Group
|
6.41% | -0.011 | 3.7% | 1.17x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
WVE
WAVE Life Sciences
|
-- | -$63.9M | -437.99% | -437.99% | 832.66% | -$46.9M |
|
EUDA
EUDA Health Holdings
|
-- | -- | -- | -- | -- | -- |
|
GDTC
CytoMed Therapeutics
|
-- | -- | -- | -- | -- | -- |
|
HAWPF
Haw Par
|
-- | -- | 6.56% | 6.62% | -- | -- |
|
MNDR
Mobile-health Network Solutions
|
-- | -- | -1223.46% | -1223.46% | -- | -- |
|
RAFLF
Raffles Medical Group
|
-- | -- | 5.51% | 5.89% | -- | -- |
WAVE Life Sciences vs. Competitors
-
Which has Higher Returns WVE or EUDA?
EUDA Health Holdings has a net margin of -167.19% compared to WAVE Life Sciences's net margin of --. WAVE Life Sciences's return on equity of -437.99% beat EUDA Health Holdings's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital WVEWAVE Life Sciences-- -$0.47 $141.6M EUDAEUDA Health Holdings-- -- -$3.5M -
What do Analysts Say About WVE or EUDA?
WAVE Life Sciences has a consensus price target of $22.30, signalling upside risk potential of 65.43%. On the other hand EUDA Health Holdings has an analysts' consensus of -- which suggests that it could grow by 33.33%. Given that WAVE Life Sciences has higher upside potential than EUDA Health Holdings, analysts believe WAVE Life Sciences is more attractive than EUDA Health Holdings.
Company Buy Ratings Hold Ratings Sell Ratings WVEWAVE Life Sciences7 1 0 EUDAEUDA Health Holdings0 0 0 -
Is WVE or EUDA More Risky?
WAVE Life Sciences has a beta of -1.210, which suggesting that the stock is 220.988% less volatile than S&P 500. In comparison EUDA Health Holdings has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock WVE or EUDA?
WAVE Life Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. EUDA Health Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. WAVE Life Sciences pays -- of its earnings as a dividend. EUDA Health Holdings pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios WVE or EUDA?
WAVE Life Sciences quarterly revenues are -$7.7M, which are larger than EUDA Health Holdings quarterly revenues of --. WAVE Life Sciences's net income of -$61.8M is higher than EUDA Health Holdings's net income of --. Notably, WAVE Life Sciences's price-to-earnings ratio is -- while EUDA Health Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for WAVE Life Sciences is 31.57x versus 64.70x for EUDA Health Holdings. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WVEWAVE Life Sciences31.57x -- -$7.7M -$61.8M EUDAEUDA Health Holdings64.70x -- -- --
-
Which has Higher Returns WVE or GDTC?
CytoMed Therapeutics has a net margin of -167.19% compared to WAVE Life Sciences's net margin of --. WAVE Life Sciences's return on equity of -437.99% beat CytoMed Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital WVEWAVE Life Sciences-- -$0.47 $141.6M GDTCCytoMed Therapeutics-- -- -- -
What do Analysts Say About WVE or GDTC?
WAVE Life Sciences has a consensus price target of $22.30, signalling upside risk potential of 65.43%. On the other hand CytoMed Therapeutics has an analysts' consensus of -- which suggests that it could grow by 78.77%. Given that CytoMed Therapeutics has higher upside potential than WAVE Life Sciences, analysts believe CytoMed Therapeutics is more attractive than WAVE Life Sciences.
Company Buy Ratings Hold Ratings Sell Ratings WVEWAVE Life Sciences7 1 0 GDTCCytoMed Therapeutics0 0 0 -
Is WVE or GDTC More Risky?
WAVE Life Sciences has a beta of -1.210, which suggesting that the stock is 220.988% less volatile than S&P 500. In comparison CytoMed Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock WVE or GDTC?
WAVE Life Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CytoMed Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. WAVE Life Sciences pays -- of its earnings as a dividend. CytoMed Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios WVE or GDTC?
WAVE Life Sciences quarterly revenues are -$7.7M, which are larger than CytoMed Therapeutics quarterly revenues of --. WAVE Life Sciences's net income of -$61.8M is higher than CytoMed Therapeutics's net income of --. Notably, WAVE Life Sciences's price-to-earnings ratio is -- while CytoMed Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for WAVE Life Sciences is 31.57x versus -- for CytoMed Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WVEWAVE Life Sciences31.57x -- -$7.7M -$61.8M GDTCCytoMed Therapeutics-- -- -- --
-
Which has Higher Returns WVE or HAWPF?
Haw Par has a net margin of -167.19% compared to WAVE Life Sciences's net margin of --. WAVE Life Sciences's return on equity of -437.99% beat Haw Par's return on equity of 6.62%.
Company Gross Margin Earnings Per Share Invested Capital WVEWAVE Life Sciences-- -$0.47 $141.6M HAWPFHaw Par-- -- $2.8B -
What do Analysts Say About WVE or HAWPF?
WAVE Life Sciences has a consensus price target of $22.30, signalling upside risk potential of 65.43%. On the other hand Haw Par has an analysts' consensus of -- which suggests that it could fall by --. Given that WAVE Life Sciences has higher upside potential than Haw Par, analysts believe WAVE Life Sciences is more attractive than Haw Par.
Company Buy Ratings Hold Ratings Sell Ratings WVEWAVE Life Sciences7 1 0 HAWPFHaw Par0 0 0 -
Is WVE or HAWPF More Risky?
WAVE Life Sciences has a beta of -1.210, which suggesting that the stock is 220.988% less volatile than S&P 500. In comparison Haw Par has a beta of 0.110, suggesting its less volatile than the S&P 500 by 88.956%.
-
Which is a Better Dividend Stock WVE or HAWPF?
WAVE Life Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Haw Par offers a yield of 3.6% to investors and pays a quarterly dividend of $0.15 per share. WAVE Life Sciences pays -- of its earnings as a dividend. Haw Par pays out 35.78% of its earnings as a dividend. Haw Par's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios WVE or HAWPF?
WAVE Life Sciences quarterly revenues are -$7.7M, which are larger than Haw Par quarterly revenues of --. WAVE Life Sciences's net income of -$61.8M is higher than Haw Par's net income of --. Notably, WAVE Life Sciences's price-to-earnings ratio is -- while Haw Par's PE ratio is 10.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for WAVE Life Sciences is 31.57x versus 10.45x for Haw Par. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WVEWAVE Life Sciences31.57x -- -$7.7M -$61.8M HAWPFHaw Par10.45x 10.66x -- --
-
Which has Higher Returns WVE or MNDR?
Mobile-health Network Solutions has a net margin of -167.19% compared to WAVE Life Sciences's net margin of --. WAVE Life Sciences's return on equity of -437.99% beat Mobile-health Network Solutions's return on equity of -1223.46%.
Company Gross Margin Earnings Per Share Invested Capital WVEWAVE Life Sciences-- -$0.47 $141.6M MNDRMobile-health Network Solutions-- -- $4.1M -
What do Analysts Say About WVE or MNDR?
WAVE Life Sciences has a consensus price target of $22.30, signalling upside risk potential of 65.43%. On the other hand Mobile-health Network Solutions has an analysts' consensus of -- which suggests that it could grow by 2452.65%. Given that Mobile-health Network Solutions has higher upside potential than WAVE Life Sciences, analysts believe Mobile-health Network Solutions is more attractive than WAVE Life Sciences.
Company Buy Ratings Hold Ratings Sell Ratings WVEWAVE Life Sciences7 1 0 MNDRMobile-health Network Solutions0 0 0 -
Is WVE or MNDR More Risky?
WAVE Life Sciences has a beta of -1.210, which suggesting that the stock is 220.988% less volatile than S&P 500. In comparison Mobile-health Network Solutions has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock WVE or MNDR?
WAVE Life Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mobile-health Network Solutions offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. WAVE Life Sciences pays -- of its earnings as a dividend. Mobile-health Network Solutions pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios WVE or MNDR?
WAVE Life Sciences quarterly revenues are -$7.7M, which are larger than Mobile-health Network Solutions quarterly revenues of --. WAVE Life Sciences's net income of -$61.8M is higher than Mobile-health Network Solutions's net income of --. Notably, WAVE Life Sciences's price-to-earnings ratio is -- while Mobile-health Network Solutions's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for WAVE Life Sciences is 31.57x versus 0.77x for Mobile-health Network Solutions. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WVEWAVE Life Sciences31.57x -- -$7.7M -$61.8M MNDRMobile-health Network Solutions0.77x -- -- --
-
Which has Higher Returns WVE or RAFLF?
Raffles Medical Group has a net margin of -167.19% compared to WAVE Life Sciences's net margin of --. WAVE Life Sciences's return on equity of -437.99% beat Raffles Medical Group's return on equity of 5.89%.
Company Gross Margin Earnings Per Share Invested Capital WVEWAVE Life Sciences-- -$0.47 $141.6M RAFLFRaffles Medical Group-- -- $811.2M -
What do Analysts Say About WVE or RAFLF?
WAVE Life Sciences has a consensus price target of $22.30, signalling upside risk potential of 65.43%. On the other hand Raffles Medical Group has an analysts' consensus of -- which suggests that it could fall by --. Given that WAVE Life Sciences has higher upside potential than Raffles Medical Group, analysts believe WAVE Life Sciences is more attractive than Raffles Medical Group.
Company Buy Ratings Hold Ratings Sell Ratings WVEWAVE Life Sciences7 1 0 RAFLFRaffles Medical Group0 0 0 -
Is WVE or RAFLF More Risky?
WAVE Life Sciences has a beta of -1.210, which suggesting that the stock is 220.988% less volatile than S&P 500. In comparison Raffles Medical Group has a beta of 0.095, suggesting its less volatile than the S&P 500 by 90.471%.
-
Which is a Better Dividend Stock WVE or RAFLF?
WAVE Life Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Raffles Medical Group offers a yield of 2.66% to investors and pays a quarterly dividend of $0.02 per share. WAVE Life Sciences pays -- of its earnings as a dividend. Raffles Medical Group pays out 78.41% of its earnings as a dividend. Raffles Medical Group's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios WVE or RAFLF?
WAVE Life Sciences quarterly revenues are -$7.7M, which are larger than Raffles Medical Group quarterly revenues of --. WAVE Life Sciences's net income of -$61.8M is higher than Raffles Medical Group's net income of --. Notably, WAVE Life Sciences's price-to-earnings ratio is -- while Raffles Medical Group's PE ratio is 27.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for WAVE Life Sciences is 31.57x versus 2.41x for Raffles Medical Group. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WVEWAVE Life Sciences31.57x -- -$7.7M -$61.8M RAFLFRaffles Medical Group2.41x 27.83x -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
How High Will Airbnb Stock Go?
Airbnb, Inc. (NASDAQ:ABNB) share price has seen substantial turbulence over…
Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 43x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
57
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
64
ARQQ alert for Dec 27
Arqit Quantum [ARQQ] is down 4.22% over the past day.
Buy
64
QMCO alert for Dec 27
Quantum [QMCO] is up 5.22% over the past day.
Buy
65
ALGS alert for Dec 27
Aligos Therapeutics [ALGS] is down 5.88% over the past day.
